) The Structural Biology Program is a new addition to the Cancer Center and resulted from the natural convergence of. 1 The necessity for structural information in cancer research; 2 The recruitment of an expert group of structural biologists and establishment of a Center for Structural Biology at the University of Virginia and; 3 The cancer-focus of many of the scientific interests of these investigators, including the multi-drug resistance P-glycoprotein, the Ras oncogene, the small GTPase, RhoA. and the phosphotyrosine-binding adapter protein, Shc. The overall goal of the Program is to integrate, through interdisciplinary collaborations, structural with functional studies of oncogenesis, metastasis and, ultimately, cancer therapy. Expertise and methodologies available include X-ray crystallography, NMR and EPR spectroscopy, atomic force and cryo-atomic force microscopy, total internal reflectance fluorescence microscopy, laser scanning confocal microscopy, X-ray mapping, energy filtered scanning electron microscopy and electron probe X-ray microanalysis. In the short time since the Program was established (May 1998) we made significant advances in high resolution structure determination of cancer related proteins (small GTPase-FAK), and initiated pilot projects (multi-drug resistance glycoprotein P). The Program also disseminates the value and use of structural methods through a seminar series featuring internationally renowned structural biologists.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA044579-11
Application #
6205194
Study Section
Subcommittee G - Education (NCI)
Project Start
1987-07-01
Project End
2004-07-31
Budget Start
Budget End
Support Year
11
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
001910777
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655
Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442
Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9
Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425
Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813
Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815
Kulling, Paige M; Olson, Kristine C; Hamele, Cait E et al. (2018) Dysregulation of the IFN-?-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. PLoS One 13:e0193429
Grant, Margaret J; Loftus, Matthew S; Stoja, Aiola P et al. (2018) Superresolution microscopy reveals structural mechanisms driving the nanoarchitecture of a viral chromatin tether. Proc Natl Acad Sci U S A 115:4992-4997
Knapp, Kiley A; Pires, Eusebio S; Adair, Sara J et al. (2018) Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget 9:8972-8984
Zhang, Xuewei; Kitatani, Kazuyuki; Toyoshima, Masafumi et al. (2018) Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer. Mol Cancer Ther 17:50-59

Showing the most recent 10 out of 539 publications